PRF Signs Non-Binding Term Sheet to Sell GridFeed to Dotz for US$1.0M
PRFX is trading near its 52-week low of $0.691 (11% above the low) on elevated volume (9.9× avg).
Summary
PRF signed a non-binding term sheet for Dotz to exclusively license and ultimately buy the GridFeed/DeepSolar platform for US$1.0 million, while PRF invests US$250,000 into Dotz's A$2.0 million placement. The deal would let PRF refocus on its OcuRing-K Phase 2 trial and healthcare programs.
Key Events · M&A and Partnerships · PRFX
-
Term Sheet Signed With Dotz Nano
A non-binding term sheet would have Dotz exclusively license GridFeed from closing and acquire the DeepSolar/GridFeed platform for US$1.0 million.
-
Payment Tied to IP Transfer
Ownership of the platform and its intellectual property transfers to Dotz once US$650,000 of the purchase price has been paid.
-
PRF Takes Dotz Equity Stake
PRF would invest US$250,000 to participate in Dotz's recently announced A$2.0 million placement, keeping exposure to GridFeed's commercialization.
-
Deal Is Non-Binding
Completion is subject to due diligence, approval by both boards of directors and execution of definitive agreements, so no proceeds are assured.
Analysis · PRFX · Life Sciences
PRF is exiting the energy software business it has been building since acquiring DeepSolar in March 2025. Under the terms, Dotz would take an exclusive license at closing and pay US$1.0 million in total, with ownership of the platform and its IP transferring once US$650,000 has been paid. PRF also puts US$250,000 into Dotz's A$2.0 million placement, so shareholders keep a stake in whatever Dotz builds. Because the deal is non-binding and requires due diligence, both boards and definitive agreements, the cash is not assured. Strategically, it narrows PRF to healthcare: the company says it will direct resources to LayerBio and the OcuRing-K Phase 2 trial, which it expects to start enrolling patients in before year-end 2026, against roughly US$11.0 million of preliminary unaudited cash at September 30, 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRFX was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.69 to $7.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.